Ovarian Low-Grade Serous Carcinoma: A Comprehe... [Gynecol Oncol. 2012] - PubMed - NCBI
Saturday, May 05, 2012
paywalled: Ovarian Low-Grade Serous Carcinoma: A Comprehensive Update
Ovarian Low-Grade Serous Carcinoma: A Comprehe... [Gynecol Oncol. 2012] - PubMed - NCBI
open access: Reproductive Technologies and the Risk of Birth Defects — NEJM
Blogger's Note: this is not cancer-specific/related but may be of interest to young cancer survivors
Reproductive Technologies and the Risk of Birth Defects — NEJM
paywalled: Psychological Distress of the Bereaved Seeking Medical Counseling at a Cancer Center
Blogger's Note/Opinion: the abstract is one of a few which is written in plain english and with an empathetic 'tone' both of which set it apart from many psycho-oncology papers
Psychological Distress of the Bereaved Seeking Medical Counseling at a Cancer Center
Abstract
Objective The death of
a loved one is one of the most stressful events in life and is related
to the physical and psychological wellbeing
of the bereaved. Some bereaved individuals seek
medical counseling to alleviate their distress. However, no studies have
focused
on the bereaved who have lost a loved one to
cancer and have asked for medical help at a cancer center as a result.
The aim
of this study was to investigate the distress of
the bereaved who sought consultation, as basic information for
considering
support.
Methods We conducted a
survey of people consulting outpatient services for bereaved families
between April 2007 and September 2009.
Data were obtained from medical records at
initial consultation and qualitatively analyzed by content analysis
using all statements
related to their distress.
Results Their
statements were classified into 11 categories, which were further
classified into six themes. The main categories of
bereavement-related distress were as follows:
(i) regret; (ii) anger; (iii) memories; (iv) loneliness; (v) anxiety;
and (vi)
hopelessness. ‘Regret’ was frequently recognized
in their distress and it includes some points related to the cancer
trajectory.
Conclusions
Psychological distresses of the bereaved who have lost a loved one and
have asked for medical counseling are revealed. Their
distresses are strongly related to the cancer
trajectory of a family member. Some of these distresses are related to
medical
misunderstanding about the course of cancer.
These findings might provide basic information for considering their
appropriate
treatment.
video: doctor who restricted his wife's appointment to one problem only - video
Blogger's Note/Opinion: while this media report is from Canada (Manitoba) this is not a country-specific issue, it is, however, not patient-centered nor patient-friendly care, watch media for upcoming 'apologies'
Canada News Videos
'Assembly line medicine' (video)
- Thu, 3 May, 2012 - CBC.ca 2:01 | 63,732 viewsMedical experts weigh in on a Manitoba man's complaint against a doctor who restricted his wife's appointment to one problem only.
paywalled: US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology (breast/ovarian mutation)
US firm corners exclusive license for RAD51C cancer gene : The Lancet Oncology
US firm corners exclusive license for RAD51C cancer gene
"Already facing a legal challenge to its BRCA1 and BRCA2 patents,
Myriad Genetics (Salt Lake City, UT, USA) has secured an exclusive
licence for another breast and ovarian cancer-associated gene, RAD51C ,
under agreement with the German Consortium for Hereditary Breast and
Ovarian Cancers, which will share exclusivity in Germany. RAD51C will be used to test patients' hereditary breast and ovarian cancer risks.
“I think it is unfortunate for both the clinical and research communities”, Jim Evans (University"
Editorial: Serrated Polyposis: The Last (or Only the Latest - Frontier of Familial Polyposis (Lynch Syndrome/familial/pre-malignant adenomas)
Wiki: Sessile serrated adenoma
In gastroenterology, a sessile serrated adenoma (abbreviated SSA), also known as sessile serrated polyp (abbreviated SSP), is a premalignant flat (or sessile) lesions of the colon, predominantly seen in the cecum and ascending colon.
Editorial: Serrated Polyposis: The Last (or Only the Latest|[quest]|) Frontier of Familial Polyposis|[quest]| : The American Journal of Gastroenterology
The American Journal of Gastroenterology 107, 779-781 (May 2012) | doi:10.1038/ajg.2012.62
Editorial: Serrated Polyposis: The Last (or Only the Latest?) Frontier of Familial Polyposis?
, and
Abstract
Serrated polyps are thought to be precursors of ~15%
of colorectal cancers and clinical criteria for a serrated polyposis
(SP) syndrome have been proposed. In this issue of American Journal of
Gastroenterology, Win et al. report that family members of individuals
who meet the clinical criteria for SP are at increased risk for
colorectal and possibly pancreatic cancer. The important data presented
by Win et al. strongly support the concept that familial SP exists and
help define the patterns of risk in this syndrome. The paper also
illustrates the difficulties of trying to define a genetic syndrome on
the basis of largely retrospective clinical data and highlights the
importance of efforts to define the genetic basis of familial SP and to
study these families in a systematic, prospective manner.
paywalled: Dosage Effect of BRCA1 and BRCA 2 Mutated Allelic Transcript (French Canadian)
Dosage Effect of BRCA1/2-Mutated Allelic Transcript:
We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation.
We aimed to discover early events associated with ovarian carcinogenesis, which could represent putative targets for preventive strategies of this silent killer tumor. We identified the first molecular signature associated with French Canadian BRCA1 or BRCA2 founder mutations in morphologically normal ovarian epithelial cells. We discovered that wild-type and mutated BRCA2 allelic transcripts were expressed not only in morphologically normal but also in tumor cells from BRCA2-8765delAG carriers. Further analysis of morphologically normal ovarian and tumor cells from BRCA1-4446C>T carriers lead to the same observation.
Our data support the idea that one single hit in BRCA1 or BRCA2 is sufficient to alter the transcriptome of phenotypically normal ovarian epithelial cells. The highest level of BRCA2-mutated allele transcript expression was measured in cells originating from the most aggressive ovarian tumor. The penetrance of the mutation and the aggressiveness of the related tumor could depend on a dosage effect of the mutated allele transcript.
paywalled: Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling
Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling: Publication year: 2012
Source: Gynecologic Oncology
Objective We sought to determine whether prophylactic oophorectomy rates changed after the introduction of a 2007 health plan clinical guideline recommending systematic referral to a genetic counselor for women with a personal or family history suggestive of an inherited susceptibility to breast/ovarian cancer.
Methods We conducted a retrospective cohort study of female members of Group Health, an integrated delivery system in Washington State. Subjects were women aged ≥35years during 2004–2009 who reported a personal or family history consistent with an inherited susceptibility to breast/ovarian cancer. Personal and family history information was collected on a questionnaire completed when the women had a mammogram. We ascertained oophorectomies from automated claims data and determined whether surgeries were prophylactic by medical chart review.....
Results Prophylactic oophorectomy rates were relatively unchanged after compared to before the guideline change, 1.0 versus 0.8/1,000 person-years, (IRR=1.2; 95% CI: 0.7-2.0), whereas bilateral oophorectomy rates for other indications decreased. Genetic counseling receipt rates doubled after the guideline change (95% CI: 1.7-2.4) from 5.1 to 10.2/1,000 person-years. During the study, bilateral oophorectomy rates were appreciably greater in women who saw a genetic counselor compared to those who did not regardless of whether they received genetic testing as part of their counseling.
Conclusion A doubling in genetic counseling receipt rates lends support to the idea that the guideline issuance contributed to sustained rates of prophylactic oophorectomies in more recent years.
Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV
Randomized Phase II Trial of Carboplatin and Paclitaxel with or without Lonafarnib in First-Line Treatment of Epithelial Ovarian Cancer Stage IIB-IV: Publication year: 2012
Source: Gynecologic Oncology
Objectives This study evaluates whether a molecular targeted therapy with the farnesyl transferase inhibitor lonafarnib added to standard chemotherapy in first-line treatment of advanced ovarian cancer (OC) could improve progression-free (PFS) and overall survival (OS).
Patients and Methods We performed a prospective randomized phase II study to compare standard therapy carboplatin (C; AUC 5) and paclitaxel (T; 175mg/m2) in primary advanced OC with or without lonafarnib (L). Lonafarnib was given in a dose of 100mg orally twice a day during chemotherapy and was increased afterwards to 200mg up to six months as a maintenance therapy.
Results 105 patients were recruited( 53 patients were randomised to receive LTC, 52 to TC). Hematologic toxicity was similar in both arms. Grade 3 and 4 non-hematological toxicity, occurred significantly more often with LTC (23% versus 4%, p=0.005) and was associated with a higher dropout rate. PFS and OS were not significantly different among both arms. The LTC arm showed inferiority in the stratum with residual tumor of more than 1cm:.....
Conclusion The addition of lonafarnib did not improve PFS or OS. Patients with a residual tumor of more than 1cm had significantly shorter PFS and OS. Incorporation of lonafarnib into future studies for primary therapy of OC is not recommended.
paywalled: Gynecologic Oncology - Green Tea for Ovarian Cancer Prevention and Treatment: A Systematic Review of the in Vitro, in Vivo and Epidemiological Studies
ScienceDirect.com - Gynecologic Oncology - Green Tea for Ovarian Cancer Prevention and Treatment: A Systematic Review of the in Vitro, in Vivo and Epidemiological Studies
Abstract
Objective
This
systematic review was conducted to examine the effects of green tea or
green tea components on the prevention and progression of epithelial
ovarian cancer.
Methods
Using Medline, EMBASE and SciVerse (last researched: July 2011), we retrieved 22 articles including 5 epidemiological studies.
Results
In
epithelial ovarian cancer cell lines, green tea and green tea
components have been shown to down regulate the expression of proteins
involved in inflammation, cell signalization, cell motility and
angiogenesis. Green tea and green tea components would induce apoptosis
and could potentiate the effects of cisplatin, a chemotherapeutic agent.
In human observational studies, significant associations between green
tea intake and both decreased ovarian cancer occurrence and better
prognosis were reported.
Conclusions
Available
literature suggests potential molecular targets for green tea in
ovarian cancer treatment and also provides data supporting the clinical
evaluation of the role of green tea or green tea components in ovarian
cancer prevention and treatment.
Highlights
►
Green tea decreases ovarian cancer-associated protein expression in
cell lines.
► Green tea-fed mice develop smaller, less vascularized ovarian cancer xenografts.
► Green tea intake could decrease ovarian cancer occurrence and recurrence in women.
► Green tea-fed mice develop smaller, less vascularized ovarian cancer xenografts.
► Green tea intake could decrease ovarian cancer occurrence and recurrence in women.
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov Phase 1 solid tumors
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery - Full Text View - ClinicalTrials.gov
| Official Title: | EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial |
This study is not yet open for participant recruitment.
Verified May 2012 by M.D. Anderson Cancer Center
First Received on May 2, 2012.
No Changes Posted
| Sponsor: | M.D. Anderson Cancer Center |
|---|---|
| Collaborator: | Ovarian Cancer Research Fund |
| Information provided by (Responsible Party): | M.D. Anderson Cancer Center ( M.D. Anderson Cancer Center ) |
| ClinicalTrials.gov Identifier: | NCT01591356 |
Purpose
The
goal of this clinical research study is to learn about the safety of
siRNA-EphA2-DOPC when given to patients with advanced, recurrent cancer. Researchers also want to learn the highest tolerable dose of this drug that can be given.
siRNA-EphA2-DOPC is designed to shut down the activity of a gene that causes tumor growth.
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov (clinical trials)
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer - Full Text View - ClinicalTrials.gov
This study is currently recruiting participants.
Verified May 2012 by Memorial Sloan-Kettering Cancer Center
First Received on April 30, 2012.
Last Updated on May 2, 2012
History of Changes
| Sponsor: | Memorial Sloan-Kettering Cancer Center |
|---|---|
| Collaborator: | Weill Medical College of Cornell University |
| Information provided by (Responsible Party): | Memorial Sloan-Kettering Cancer Center ( Memorial Sloan-Kettering Cancer Center ) |
| ClinicalTrials.gov Identifier: | NCT01591772 |
Purpose
The
purpose of this study is to learn about possible changes in brain
anatomy and function, and in thinking abilities, such as memory skills,
in patients with ovarian cancer who receive treatment with chemotherapy. Cancer
patients treated with chemotherapy may experience changes in thinking
abilities, and these may interfere with quality of life. Most of the
research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.
Subscribe to:
Posts
(
Atom
)
Posts
